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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder
characterised by seizures, mental retardation and the development of hamartomas in a variety of
organs and tissues. The disease is caused by mutations in either the TSC1 gene on chromosome
9q34, or the TSC2 gene on chromosome 16p13.3. The TSC1 and TSC2 gene products, TSC1 and
TSC2, interact to form a protein complex that inhibits signal transduction to the downstream
effectors of the mammalian target of rapamycin (mTOR).
Methods: We have used a combination of different assays to characterise the effects of a number
of pathogenic TSC2 amino acid substitutions on TSC1–TSC2 complex formation and mTOR
signalling.
Results: We used these assays to compare the effects of 9 different TSC2 variants (S132C, F143L,
A196T, C244R, Y598H, I820del, T993M, L1511H and R1772C) identified in individuals with
symptoms of TSC from 4 different families. In each case we were able to identify the pathogenic
mutation.
Conclusion: Functional characterisation of TSC2 variants can help identify pathogenic changes in
individuals with TSC, and assist in the diagnosis and genetic counselling of the index cases and/or
other family members.
Background
Tuberous sclerosis complex (TSC) is an autosomal domi-
nant disorder characterised by seizures, mental retarda-
tion and the development of hamartomas in a variety of
organs and tissues [1]. The disease is caused by mutations
in either the TSC1 gene on chromosome 9q34 [2], or the
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gosity studies at the TSC1 and TSC2 loci in TSC-associated
lesions indicate that TSC1 and TSC2 are tumour suppres-
sor genes [1]. Comprehensive screens for mutations at
both the TSC1 and TSC2 loci have been performed in sev-
eral large cohorts of TSC patients and a wide variety of dif-
ferent pathogenic mutations have been described [4-10].
In most studies approximately 20% of the identified
mutations are either missense changes or small, non-trun-
cating insertions/deletions, predominantly in the TSC2
gene.
The phenotypic expression of TSC is highly variable and
in some cases it can be difficult to establish a definitive
clinical diagnosis. Generally the diagnosis is made based
on multiple clinical criteria that are categorized into
major and minor features [11]. The presence of 2 major
features, or one major and 2 minor features, is sufficient
for a definite diagnosis. In recent years, mutation analysis
has become an additional diagnostic tool in familial as
well as sporadic TSC. However, it is sometimes difficult to
establish whether an identified nucleotide change, partic-
ularly a missense change, is a genuine pathogenic muta-
tion, or a (rare) polymorphism. In familial cases where a
missense change cosegregates with TSC, or in cases where
key relatives are not available for testing, a distinction can-
not be made on genetic grounds alone. Furthermore,
many tools for the analysis of amino acid substitutions
[12-14], may not predict the effect of a particular substitu-
tion reliably.
The TSC1 and TSC2 gene products, TSC1 and TSC2, inter-
act to form a protein complex which acts as a GTPase acti-
vating protein (GAP) for the rheb GTPase, preventing the
rheb-GTP-dependent stimulation of cell growth through
the mammalian target of rapamycin (mTOR) [15]. In cells
lacking either TSC1 or TSC2, the downstream targets of
mTOR, p70 S6 kinase (S6K) and ribosomal protein S6, are
constitutively phosphorylated [16,17]. The identification
of the role of the TSC1–TSC2 complex in regulating signal
transduction through mTOR has made it possible to
assess the activity of different TSC1 and TSC2 variants. The
effects of amino acid changes on TSC1–TSC2 complex for-
mation, on the activation of rheb GTPase activity by the
complex, and on the phosphorylation status of S6K and
S6, the downstream effectors of mTOR, can be determined
[18,19].
Here, we apply assays of TSC1–TSC2 function to assist in
the identification, diagnosis and counselling of 4 families
with TSC. In each index case at least 2 changes in the TSC2
gene were detected. To identify the disease-causing muta-
tion in each family we characterised the effects of the
changes on the activity of the TSC1–TSC2 complex. In
each case we were able to identify the pathogenic TSC2
variant. Our analysis demonstrates that biochemical
assays can help resolve otherwise intractable problems in
clinical genetic diagnostics.
Methods
Mutation analysis
DNA was extracted from peripheral blood using standard
techniques. Mutation analysis was performed using a
combination of single-strand conformational polymor-
phism analysis, denaturing gradient gel electrophoresis,
direct sequencing, Southern blotting and fluorescence in
situ hybridisation, as previously described [8]. In addition,
the multiplex ligation-dependent probe amplification
assay was performed (MRC Holland, The Netherlands).
TSC2 sequence changes were numbered according to the
original cloning paper [3].
To investigate whether the changes had an effect on RNA
splicing, 3 different splice-site prediction programs [12-
14]. were used. Amino acid substitutions were evaluated
using the PAM 250 [15], BLOSUM 62 [16] and Grantham
[17] matrices and SCANSITE [23].
Generation of constructs and antisera
Expression constructs encoding the identified variants
were derived using the Stratagene QuikChange site-
directed mutagenesis kit and in each case verified by
sequencing the complete open reading frame. All the
other constructs used in this study have been described
previously [21,24,25]. Polyclonal rabbit antisera specific
for human TSC1 and TSC2 have been described previ-
ously [25]. Other antibodies were purchased from Cell
Signaling Technology.
Transfections, immunocytochemistry, immunoblotting,
immunoprecipitation assays and the in vitro assay of rheb
GTPase activity were performed as described previously
[21].
Results
Patient characteristics
Family 1
(Figure 1A) The index case (II:2) died shortly after birth
due to a solitary rhabdomyoma in the right ventricle of
the heart. Post-mortem examination did not reveal any
other findings indicative of TSC. Both parents underwent
a full clinical evaluation. Dermatological, cardiological,
ophthalmological, neurological and radiological exami-
nations were negative for signs of TSC except for one nail
groove and one hypomelanotic macule in individual I:1.
The sibling of the index case (II:1) was healthy, but was
not investigated further. At the first trimester of the third
pregnancy, mutation analysis of the index case had not
been completed and prenatal DNA testing could not be
offered. Fetal echocardiography did not reveal any heartPage 2 of 12
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Pedigrees of the investigated familiesFigu  1
Pedigrees of the investigated families. (A) Family 1, (B) Family 2, (C) Family 3 and (D) Family 4. Arrows indicate the index cases. 
Clear symbols indicate no signs or symptoms of TSC; 1/4-filled symbols indicate one minor feature of TSC; 1/2-filled symbols 
indicate possible TSC; 3/4-filled symbols indicate probable TSC, filled symbols indicate definite TSC, and individuals with epi-
lepsy only are indicated. A question mark indicates individuals where no clinical data was available. Genotypes are shown for 
the individuals where DNA was available for testing.
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healthy child (II:3).
Family 2
(Figure 1B) The index case (III:4) had multiple
hypomelanotic macules and dental pits, epilepsy and
electroencephalographic abnormalities, and was diag-
nosed with 'probable TSC'. One of the parents of the index
case (II:10) had multiple dental pits and a computer tom-
ography scan revealed 2 small calcifications in the nucleus
caudatus which were not typical for TSC. Magnetic reso-
nance imaging was performed and showed no additional
abnormalities. Individual II:9, the other parent of the
index case, had a single 2 centimetre cyst in the left kidney
and a single ash leaf-shaped area of hypopigmentation,
insufficient for a diagnosis of TSC. Individual II:11, the
sibling of II:10, had neurological and ophthalmological
problems and died at the age of 13 due to status epilepti-
cus. Individual III:1, the half-sibling of the index case and
the child of individual II:9, had a history of possible epi-
lepsy at the age of 3 years and was again diagnosed with
epilepsy at 12 years of age. A subsequent full diagnostic
work-up identified cortical tubers and 7 hypomelanotic
macules, fulfilling the diagnostic criteria for definite TSC.
Individual II:8 had multiple dental pits and 10 irregular
hypopigmentations, atypical for TSC.
Family 3
(Figure 1C) The index case (II:1) was diagnosed with def-
inite TSC. One parent (I:2) did not show any clinical signs
of TSC, and there was no information on the other parent
(I:1).
Family 4
(Figure 1D) The index case (II:1) was diagnosed with def-
inite TSC. Individual I:1, the parent of the index case, had
angiomyolipoma but no other reported signs of TSC, and
individual II:2, the sibling of the index case had epilepsy,
but no other signs of TSC.
Mutation analysis
Family 1
The index case (II:2) was heterozygous for 2 changes in
the TSC2 gene: TSC2 2476delATC (deletion of isoleucine
at codon 820, I820del) and TSC2 5332C>T (arginine to
cysteine substitution at codon 1772, R1772C). Analysis of
the parents indicated that the index case had inherited
one change from each parent. No DNA was available from
other relatives.
Family 2
The index case (III:4) was heterozygous for 2 missense
changes: TSC2 2996C>T (threonine to methionine substi-
tution at codon 993, T993M) and TSC2 4550T>A (leucine
to histidine amino acid substitution at position 1511,
L1511H). Analysis of additional family members (indi-
viduals I:3, I:4, II:9, II:10 and III:3) confirmed that one
substitution was paternal in origin and the other mater-
nal.
Family 3
The index case (II:1) was heterozygous for 2 missense
changes: TSC2 604G>A (alanine to threonine substitution
at codon 196, A196T) and TSC2 1810T>C (tyrosine to his-
tidine substitution at codon 598, Y598H). Neither substi-
tution was detected in parent I:2, and DNA from parent
I:1 was not available for testing.
Family 4
The index case (II:1) was heterozygous for 3 missense
changes in the TSC2 gene: TSC2 413C>G (serine to
cysteine substitution at codon 132, S132C), TSC2
447C>G (phenylalanine to leucine substitution at codon
143, F143L) and TSC2 748T>C (cysteine to arginine sub-
stitution at codon 244, C244R). The S132C and F143L
substitutions were inherited from parent I:1. No DNA was
available from the other parent.
Comparison of the allele ratios of the index cases and par-
ents did not reveal any evidence for somatic mosaicism in
the leukocyte DNA from any of the families studied. None
of the changes showed an effect on splicing according to
the 3 splice-site prediction programs used.
As shown in Table 1, the identified amino acid changes
were compared using the PAM 250 [15], BLOSUM 62 [16]
and Grantham matrices [17]. In addition, the degree of
conservation of the amino acid residues in different meta-
zoan species was compared, as shown in Table 2.
Functional analysis
Families 1 and 2
The genetic data from families 1 and 2 indicated that in
both families the index case had inherited a different, rare
TSC2 variant from each parent. To determine whether the
I820del, R1772C, T993M and L1511H variants corre-
sponded to pathogenic mutations, the biochemical activ-
ity of each variant was compared to wild-type TSC2 and a
known, pathogenic TSC2 missense variant (R611Q) using
a variety of functional assays.
To investigate the ability of the TSC2 I820del, R1772C,
T993M and L1511H variants to interact with TSC1, coim-
munoprecipitation experiments were performed using
antibodies specific for TSC1. As shown in Figures 2A and
2B, coimmunoprecipitation of the TSC2 I820del variant
was reduced compared to wild-type TSC2, but was not
prevented completely (compare the I820del variant to the
R611Q variant). The R1772C, T993M and L1511H aminoPage 4 of 12
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precipitation.
Next, the activation of rheb GTPase activity by the immu-
noprecipitated variant TSC1–TSC2 complexes was
assayed. As shown in Figure 2C, in the presence of the
wild-type TSC1–TSC2 complex the ratio of rheb-bound
GDP to GTP was 3-fold higher than in the presence of
TSC1 alone (control GDP/GTP = 0.4; wild-type GDP/GTP
= 1.4). Coimmunoprecipitation of the TSC2 I820del vari-
ant was reduced compared to wild-type TSC2, and conse-
quently the activation of rheb GTPase activity was also
reduced (wild-type GDP/GTP = 1.4; I820del GDP/GTP =
0.9).
The immunoprecipitated R1772C and T993M variant
complexes increased the GDP/GTP ratio more than 4-fold
above the control value, and were therefore both at least
as active as wild-type TSC2 (wild-type GDP/GTP = 1.4;
R1772C and T993M GDP/GTP = 1.9). In contrast,
although TSC1–TSC2 coimmunoprecipitation was unaf-
fected by the L1511H substitution, the activation of rheb
GTPase activity was reduced 3-fold compared to wild-type
(wild-type GDP/GTP = 1.4; L1511H GDP/GTP = 0.5).
To determine whether the TSC2 I820del, R1772C, T993M
and L1511H variants affected mTOR activity, the variants
were overexpressed together with TSC1 and S6K in human
embryonal kidney 293 cells. Phosphorylation of the exog-
enous S6K linker domain (T389), as detected by immuno-
blotting, was used as a read-out for mTOR activity. As
shown in Figure 2E and 2F, S6K T389 phosphorylation
was increased in the presence of the TSC2 I820del,
L1511H and R611Q variants, compared to wild-type
TSC2 and the R1772C and T993M variants. To confirm
these findings, TSC1 and the TSC2 variants were overex-
pressed in Tsc2 -/- mouse embryo fibroblasts (MEFs) [16].
The S235/S236 phosphorylation of S6 in the MEFs
expressing the TSC2 variants was determined by double-
label immunofluorescent microscopy, as described previ-
ously [21]. As shown in Figure 2D, expression of the TSC2
R1772C and T993M variants suppressed S6 phosphoryla-
tion in more than 90% of the transfected cells, similar to
wild-type TSC2. In contrast, less than 20% of the MEFs
expressing the TSC2 I820del, L1511H or R611Q variants
showed inhibition of S6 phosphorylation. Therefore, in
both assays, the TSC2 I820del and L1511H variants were
unable to inhibit mTOR, indicating that both these vari-
ants are pathogenic, while the TSC2 R1772C and T993M
Table 1: Scores of the BLOSUM 62, PAM 250 and Grantham matrices. BLOSUM 62 scores range between -4 and 11, PAM 250 scores 
between -8 and 17, and Grantham scores between 5 and 215. For the BLOSUM 62 and PAM 250 matrices, a more negative score 
corresponds to a less conservative amino acid change. For the Grantham matrix, a higher number reflects a less conservative change.
Amino Acid Substitution Family BLOSUM 62 PAM 250 Grantham
TSC2 R1772C 1 -3 -4 180
TSC2 T993M 2 -1 -1 81
TSC2 L1511H 2 -3 -2 99
TSC2 A196T 3 0 1 58
TSC2 Y598H 3 2 0 83
TSC2 S132C 4 -1 0 112
TSC2 F143L 4 0 2 22
TSC2 C244R 4 -3 -4 180
Table 2: Evolutionary conservation of the variant TSC2 amino 
acids. Inter-species conservation of the TSC2 S132, F143, A196, 
C244, Y598 I820, T993, L1511 and R1772 amino acids is shown.
Family 1
I820 R1772
human PDIIIKALP GQRKRLISS
mouse PDIIIKALP GQRKRLISS
rat PDIIIKALP GQRKRLISS
pufferfish PDIMIKLLP GQRKRLVST
fruitfly PEALMRKLP no homology
Family 2
T993 L1511
human SRIQTSLTS SVQLLDQIP
mouse SRIQTSLTS SVQLLDQIP
rat SRIQTSLTS SVQLLDQIP
pufferfish RRMHTSTTT AVKVLDQMP
fruitfly no homology AVSLIDLVP
Family 3
A196 Y598
human DEYIARM V IQLHYKHSY
mouse DEYIASM V IQLHYKHGY
rat DEYIAPM V IQLHYKHGY
pufferfish DQNVASM V LQLHYKNKY
fruitfly DKDILVGIV LELHYERPK
Family 4
S132 F143 C244
human KDYPS NED RLEVFKALT IVTLCRTIN
mouse KDYPS NED RLEVFKALT IITLCRTIN
rat KDYPS NED RLEVFKALT IITLCRTVN
pufferfish RDYQPCNED RLEVFKALT IITLCRTVN
fruitfly IQNHEARED LLELLDTLT ITTLCRTVNPage 5 of 12
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Results of the functional assays on the TSC2 variants identified in family 1 (variants I820del and R1772C) and family 2 (variants T993M and L1511H)Fig re 2
Results of the functional assays on the TSC2 variants identified in family 1 (variants I820del and R1772C) and family 2 (variants 
T993M and L1511H). (A) Interaction between TSC1 and TSC2 variants. TSC1–TSC2 complexes were immunoprecipitated 
with antibodies specific for exogenous TSC1 from HEK 293 cells over-expressing TSC1 and wild-type TSC2 (wt) or TSC1 and 
the TSC2 variants. (B) Interaction between TSC1 and TSC2 variants. Ratio of coimmunoprecipitated TSC2:TSC1, as detected 
by immunoblotting, was estimated by densitometry scanning (Total Scan). (C) In vitro rheb GAP activity of immunoprecipitated 
TSC1–TSC2 complexes. Rheb-bound GDP/GTP ratios were determined after 90 minutes incubation with the immunoprecipi-
tated wild-type TSC1–TSC2 complex (wt), protein A beads only (control), TSC1 only, or TSC1–TSC2 variant complexes. 
Rheb-bound GDP/GTP prior to addition of the TSC1–TSC2 complexes is shown (t = 0). (D) Inhibition of S6 phosphorylation 
in Tsc2 -/- MEFs. Percentage of Tsc2 -/- MEFs transfected with expression constructs encoding TSC1 and wild-type TSC2, or 
TSC1 and the TSC2 variants, and showing inhibition of S6 phosphorylation. Data from at least 3 separate experiments are 
shown. (E) TSC2-dependent inhibition of S6K-T389 phosphorylation. S6K, TSC1 and wild-type TSC2 (wt), or S6K, TSC1 and 
the TSC2 variants, were coexpressed in HEK 293 cells. Phosphorylation of S6K at the T389 position was determined by immu-
noblotting. A representative example of at least 3 separate experiments is shown. (E) TSC2-dependent inhibition of S6K-T389 
phosphorylation. Ratio of total S6K:T389-phosphorylated S6K, as detected by immunoblotting, was estimated by densitometry 
scanning (Total Scan). Mean ratios relative to TSC2 wild-type (wt) are shown.
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therefore not pathogenic amino acid substitutions.
Families 3 and 4
In families 3 and 4, the clinical and genetic data was
incomplete. Multiple TSC2 variants were identified in the
index cases, but it was not clear if they were de novo, or had
been inherited from an untested parent. It was also
unclear whether the changes were confined to the same
allele. Therefore, to investigate the effects of the changes
on the ability of the TSC1–TSC2 complex to antagonise
mTOR signalling, TSC2 variants containing the different
combinations of amino acid substitutions were character-
ised.
As shown in Figure 3A and 3B, S6K T389 phosphorylation
was inhibited by expression of the TSC2 S132C, F143L
and A196T single variants, and by the S132C/F143L dou-
ble variant. In contrast, expression of the C244R and
Y598H single variants did not inhibit S6K phosphoryla-
tion, and expression of TSC1 was reduced in the presence
of these variants. Consistent with these observations, the
S132C/F143L/C244R triple variant and A196T/Y598H
double variant were unable to inhibit S6K phosphoryla-
tion and TSC1 expression was reduced in the presence of
these variants, compared to in the presence of wild-type
TSC2. To provide confirmation for these data, double-
label immunofluorescent microscopy was performed to
determine whether S6 phosphorylation was down-regu-
lated in Tsc2 -/- MEFs expressing the different variants. As
shown in Figure 3C, expression of the TSC2 C244R,
S132C/F143L/C244R, Y598H and A196T/Y598H variants
was unable to inhibit S6 phosphorylation in the Tsc2 -/-
MEFs. Therefore, in both assays, the Y598H and C244R
variants correspond to the pathogenic mutations in fami-
lies 3 and 4 respectively.
Discussion
Mutation analysis of the TSC1 and TSC2 genes in individ-
uals with TSC, and in those suspected of having the dis-
ease, facilitates the diagnosis of TSC, and can help genetic
counselling. In most cases, analysis of the patient's DNA
results in the identification of a pathogenic mutation.
However, in some cases it is impossible to determine from
the genetic data alone whether specific, identified changes
are pathogenic or not. This can be a particular problem
when a change co-segregates with signs of TSC in a single
family. To address such cases, we have performed func-
tional analysis of the predicted protein products of the
TSC2 variants identified in 4 families with TSC.
In families 1 and 2 the index case did not fulfil the diag-
nostic criteria for TSC and had inherited 2 non-truncating
TSC2 nucleotide changes, one from each parent. It was
not possible to determine from the clinical and genetic
data alone whether the families were affected by TSC and,
if that was the case, which nucleotide change was the dis-
ease-causing mutation.
In families 3 and 4, in which the index case did fulfil the
diagnostic criteria for TSC, it was impossible to determine
whether the identified TSC2 variant was pathogenic
because essential genetic and/or clinical data was not
available. In all the above cases we analysed the effect of
the identified changes on the activity of the TSC1–TSC2
complex in order to establish which of the changes were
pathogenic mutations.
Families 1 and 2
The in vitro GTPase activity of rheb was not stimulated in
the presence of the TSC2 I820del and L1511H variants,
and neither variant was able to inhibit S6K and S6 phos-
phorylation as effectively as wild-type TSC2, or the
R1772C and T993M variants. In addition, the I820del var-
iant formed a complex with TSC1 less efficiently than
wild-type TSC2. The I820del and L1511H changes there-
fore had similar effects to other pathogenic TSC2 missense
mutations, disrupting the function of the TSC1–TSC2
complex in vitro. We classified the I820del and L1511H
variants as pathogenic mutants. The R1772C and T993M
substitutions had no effect on TSC1–TSC2 activity in the
assays used and were therefore classified as rare polymor-
phisms.
In utero cardiac rhabdomyoma was the only sign of TSC in
the index patient of family 1 (individual II:2). Rhabdomy-
oma is the most common foetal and neonatal cardiac
tumour and although it can be associated with several dif-
ferent genetic disorders, TSC is implicated in as many as
two-thirds of the cases [26]. Confirmation of the inactivat-
ing nature of the TSC2 I820del mutation identified in
family 1 meant that a diagnosis of TSC could be assigned
to individuals I:1 and II:2 with more certainty. Previously,
the very mild presentation of the disease in individal I:1
had made diagnosis difficult. Mutation analysis, comple-
mented by functional assays, was required to establish
whether this individual carried a pathogenic TSC2 muta-
tion, and the identification of a mutation in this individ-
ual has implications for the family in regard to decisions
about having additional children and to the risk of other
relatives of the parent. Somatic mosaicism in individual
I:1 could not be rigorously excluded, since only leukocyte
DNA was available for analysis. Therefore, the recurrence
risk for this couple is up to 50%.
Analysis of the TSC2 I820del mutant indicated that the
isoleucine residue helps to stabilise TSC1–TSC2 binding.
However, since some TSC1–TSC2 binding was detected,
and some rheb GAP activity could also be measured, it is
possible that the TSC2 I820del variant retains some activ-Page 8 of 12
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Results of the functional assays on the TSC2 variants identified in family 3 (variants A196T and Y598H) and family 4 (variants S132C, F143L and C244R)Fig re 3
Results of the functional assays on the TSC2 variants identified in family 3 (variants A196T and Y598H) and family 4 (variants 
S132C, F143L and C244R). (A) TSC2-dependent inhibition of S6K-T389 phosphorylation. S6K, TSC1 and wild-type TSC2 (wt), 
or S6K, TSC1 and the TSC2 variants, were overexpressed in HEK 293 cells. Phosphorylation of S6K at the T389 position was 
determined by immunoblotting. A representative example of at least 3 separate experiments is shown. (B) TSC2-dependent 
inhibition of S6K-T389 phosphorylation. Ratio of total S6K:T389-phosphorylated S6K, as detected by immunoblotting, was 
estimated by densitometry scanning (Total Scan). Mean ratios relative to TSC2 wild-type (wt) are shown.(C) Inhibition of S6 
phosphorylation in Tsc2 -/- MEFs. Percentage of Tsc2 -/- MEFs transfected with expression constructs encoding TSC1 and wild-
type TSC2, or TSC1 and the TSC2 variants, and showing inhibition of S6 phosphorylation. Data from at least 3 separate exper-
iments are shown.
BMC Medical Genetics 2008, 9:10 http://www.biomedcentral.com/1471-2350/9/10ity in vivo. This provides a possible explanation for the
mild symptoms in individual I:1. The second variant iden-
tified in family 1, TSC2 R1772C, did not have a deleteri-
ous effect on the activity of the TSC1–TSC2 complex. This
was somewhat surprising as the R1772 residue is part of
the consensus extracellular signal-regulated kinase (ERK)
phosphorylation site that has been shown to be involved
in regulating the activity of the complex [27,28]. Indeed,
SCANSITE [23] indicated that the R1772C substitution
destroys the putative ERK phosphorylation site. Further-
more, both the BLOSUM 62 and PAM 250 matrices indi-
cated that the R1772C substitution is likely to have a
deleterious effect on TSC2 structure. One possibility is
that under certain conditions, the R1772C substitution
may have a modifying effect on the TSC1–TSC2 complex,
enhancing TSC1–TSC2 activity by preventing the Erk-
dependent down-regulation of the complex [28]. This
may explain the increased rheb GTPase activity measured
in the presence of the TSC2 R1772C variant, compared to
wild-type TSC2 (wild-type TSC2 GDP/GTP ratio = 1.4;
R1772C GDP/GTP ratio = 1.9; Figure 2B).
Both the 2476delATC (I820del) and 5332C>T (R1772C)
variants have been identified in TSC patients by other
researchers [29-31]. Strizheva et al. [30] suggested that the
R1772C substitution could be a pathogenic change while
Langkau et al. [31] concluded that it was a polymorphism.
The status of the I820del change was not certain [29]. Our
analysis is consistent with the findings of Langkau et al.
and, in addition, indicates that the TSC2 I820del variant
is pathogenic. Furthermore, this example demonstrates
that predictions about the pathogenicity of missense
changes based on the results of the BLOSUM 62, PAM 250
and Grantham matrices are not always reliable.
In family 2, mutation analysis resulted in the identifica-
tion of 2 novel TSC2 missense changes, 2996C>T
(T993M) and 4550T>A (L1511H), in the index case (indi-
vidual III:4). Individual III:1, the half-sibling of the index
case was later diagnosed with TSC on the basis of the
accepted clinical criteria and was found to carry the TSC2
4550T>A (L1511H) substitution only. No other nucle-
otide changes were identified in the TSC1 or TSC2 genes
in either individual. The identification of the TSC2
L1511H change in individual III:1 excluded the T993M
change as the common cause of TSC in this family. How-
ever, it did not confirm the pathogenicity of the TSC2
L1511H change. The presence of multiple dental pits in
both individual II:8 and individual II:10 suggested that
the signs of TSC in individuals III:1 and III:4 could be
caused by two different mutations, inherited from indi-
viduals II:8 and II:12 respectively. However, the func-
tional tests confirmed the pathogenic nature of the TSC2
L1511H substitution, indicating that this was the disease-
causing mutation in both cases. The substitution of a basic
histidine residue for a nonpolar leucine residue at posi-
tion 1511 did not affect the TSC1–TSC2 interaction, but
did abrogate the rheb GAP activity of the TSC1–TSC2
complex. Although L1511 is outside the predicted TSC2
GAP domain [3], it is clearly necessary for activity. The
substitution of a polar threonine for nonpolar methione
at position 993 had no deleterious effect on the TSC1–
TSC2 interaction or on the activity of the complex. The
T993M substitution occurs at a possible site of protein
kinase B (PKB)-dependent phosphorylation [27], and
may therefore inhibit PKB-mediated inactivation of the
TSC1–TSC2 complex. This may explain why the TSC2
T993M variant, like the R1772C variant, had a higher in
vitro rheb GAP activity than wild-type TSC2 (wild-type
TSC2 GDP/GTP ratio = 1.4; T993M GDP/GTP ratio = 1.9;
Figure 2B). The T993M polymorphism may therefore also
act as a positive modifier of TSC1–TSC2 activity.
In family 3, 2 missense changes (TSC2 604G>A (A196T)
and TSC2 1810T>C (Y598H)) were identified in the index
case (individual II:1). Since there was no genetic or clini-
cal data on one of the parents, it was not possible to deter-
mine whether either of the changes was responsible for
TSC in this individual. Both variants had been identified
previously in other TSC patients [29], however in these
patients it was also not clear whether the changes were
pathogenic. Functional analysis indicated that the TSC2
Y598H substitution reduced TSC1–TSC2 binding and the
TSC1–TSC2 dependent inhibition of mTOR activity. In
contrast, the A196T substitution did not affect TSC2 activ-
ity. Therefore, the Y598H substitution was responsible for
TSC in individual II:1, as well as in other TSC patients
[29], and the A196T substitution is a rare polymorphism.
In family 4, 3 missense changes were identified in the
TSC2 gene. The 413C>G (S132C) and 447C>G (F143L)
substitutions were inherited from a parent with symp-
toms suggesting TSC. The third substitution, 748T>C
(C244R), was either a de novo mutation, or was inherited
from the other parent, on whom there was no clinical or
genetic data. None of these changes have been described
previously [29]. One possibility in this family was that the
combination of missense changes was responsible for the
TSC phenotype. Therefore we tested all the individual
TSC2 single amino acid variants (S132C, F143L and
C244R) as well as the TSC2 S132C/F143L double variant
and TSC2 S132C/F143L/C244R triple amino acid variant.
Neither the S132C nor the F143L changes had a signifi-
cant effect on TSC1–TSC2 function. In some assays the
F143L variant appeared less active than wild-type TSC2,
but still had the ability to significantly inhibit mTOR
activity. In contrast, the C244R amino acid substitution
reduced TSC1–TSC2 binding and was unable to inhibit
mTOR activity, either alone or in combination with the
S132C and F143L variants. We concluded that the C244RPage 10 of 12
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case. Individual I:1 tested negative for the TSC2 748T>C
(C244R) substitution, but was diagnosed with angiomy-
olipomas. Although insufficient for a definite diagnosis of
TSC, the incidence of angiomyolipomas is high in the TSC
patient population. One possibility is that this individual
is a mosaic for the TSC2 748T>C (C244R) susbstitution,
and that the angiomyolipoma originates from these
mosaic cells. An alternative explanation is that the TSC2
447C>G (F143L) substitution does have an effect on TSC2
function, sufficient to allow the formation of angiol-
ipoma. The F143L amino acid substitution may therefore
be a negative modifier of TSC1–TSC2 activity, in contrast
to the R1772C and T993M substitutions identified in fam-
ilies 1 and 2, that, in some assays, appeared to increase
TSC1–TSC2 activity. Although there was no evidence in
family 1 or family 2 for the non-pathogenic TSC2 variant
acting in trans to neutralise the pathogenic variant, it will
be interesting to determine whether there are 'hyperactive'
TSC1 and TSC2 variants that can (partially) compensate
for the presence of pathogenic TSC1 and TSC2 variants.
Improving the sensitivity and reliability of the assays of
TSC1–TSC2 activity will allow us to more accurately
define the activity of different TSC1 and TSC2 variants.
We did not investigate the other putative functions of
TSC2 since, in each family, we were able to differentiate
between the TSC2 variants on the basis of their inhibition
of mTOR signalling. However, it may also be informative
to investigate the effects of pathogenic and non-patho-
genic amino acid substitutions on the other proposed
functions of TSC2, such as the regulation of p27 [32].
Care must always be taken in the interpretation of nucle-
otide or amino acid changes identified during molecular
genetic investigations. As the examples described here
demonstrate, both the affection status of individuals in a
family and the nature of the nucleotide changes identified
in those individuals are not always clear. To distinguish
between pathogenic mutations and harmless polymor-
phisms, we have analysed the effects of different amino
acid changes on the activity of the TSC1–TSC2 complex.
In each case we have been able to distinguish pathogenic
TSC2 variants from rare polymorphic variants, and
thereby identify the mutation in each family. We have
shown that functional assays can be a useful tool to com-
plement traditional DNA-based mutation analysis in TSC.
Identification of the pathogenic mutations in the TSC
families described here enabled not only genetic counsel-
ling and prenatal testing for future pregnancies but also
improved the diagnosis of affected family members to
facilitate their critical clinical care. The use of functional
assays to differentiate between polymorphisms and path-
ogenic mutations, in TSC and other diseases, will facilitate
not only the identification of pathogenic mutations but
will also help establish how different amino acid residues
contribute to protein function.
Conclusion
Deletion of isoleucine at amino acid residue 820 of TSC2
and the TSC2 L1511H, C244R and Y598H amino acid
substitutions are sufficient to cause TSC. The TSC2
R1772C, T993M, S132C, F143L and A196T substitutions
are rare polymorphisms that do not inhibit TSC1–TSC2
function, and do not cause TSC.
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